This study not only reveals a novel mechanism of action of lncRNA PTTG3P in promoting the occurrence and metastasis of NSCLC, but also provides an experimental basis for the use of PTTG3P, ILF3, E2F1, and MAP2K6 as biomarkers and therapeutic targets for the diagnosis and treatment of NSCLC. The gene discussed is MAP2K6; the disease is non-small cell lung carcinoma.